Richard Kaplan, Professor Emeritus of Oncology

Rick trained in medical oncology in its early years as a medical specialty and spent 16 years at the US National Cancer Institute (NCI), part of NIH.  He served as Chief of the US NCI’s Clinical Investigations Branch at CTEP, which is the NIH unit responsible for supervision of all NCI-funded extramural clinical trials. 

He came to the UK from the US in 2004 to serve as Associate Director of the then newly established UK National Cancer Research Network (NCRN, which subsequently evolved into UKCRN), and to head up pharma liaison for NIHR.  He also held a Chair at Leeds University and maintained an oncology practice at St James’ Hospital.  In 2008 he began working part time at MRC CTU and shifted to full time at MRC CTU, UCL and UCH as of 2010.

He has also served in various advisory positions for international clinical trials organisations, including the Cancer Clinical Trials Group in Canada, the EORTC, and the French NCI (INCA).

He is now in an emeritus role and able to devote time to other interests, which include theatre, opera, and guiding and archiving work at Broughton Castle, near Banbury, the home of the 21st Lord Saye & Sele.

Selected publications

Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M. Evaluating many treatments and biomarkers in oncology: a new design. J Clinical Oncol 31(36):4562-68, 2013 [doi: 10.1200/JCO.2013.50.7905, 18 Nov2013; PMID: 24248692]

Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT, Sampson JR, Seymour MT, Nichols LL, Kenny SL, Nelson A, Sampson CM, Hodgkinson E, Bridgewater JA, Furniss DL, Roy R, Pope MJ, Pope JK, Parmar M, Quirke P, Kaplan R. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?  British Journal of Cancer 110(9):2178-2186, 2014 [doi: 10.1038/bjc.2014.182  PMID: 24743706]

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Emberton M. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. The Lancet 389:815-22, 2017 [doi:10.1016/S0140-6736(16)32401-1; PMID: 28110982]

Parmar MKB, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PPJ, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.  Clinical Trials 14:451-461, 2017. [dorg/10.1177/1740774517725697; PMID: 28830236]

Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.  Lancet 2019 Dec 7;394(10214):2084-2095. [doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29., PMID: 31791688]

Research Interests

  • Large-scale clinical trials
  • Innovative clinical trials design

Research Areas

Related Studies

UCL Profiles